Company History
2009
Our Company was established in Beijing, China as our headquarters to
commence research and development of biotechnology in the China
2011
Developed ESC/HR-based gene editing technology platform and delivered our
gene editing services to our first customer
2014
Developed CRISPR/EGE-based gene editing technology, which enables
simultaneous gene knock-in of two genes in rats
Developed the severe immunodeficient B-NDG™ mice and developed a series of
immune checkpoint humanized mice based on the genetic background of
C57BL/6
2013
Completed the series A round financing and raised an aggregate amount of
approximately RMB35 million
2015
Established a comprehensive pharmacology service platform, covering
cell-based functional assays, pharmacokinetic assays and drug metabolism
assays
Completed the series B round financing and raised an aggregate amount of
approximately RMB40 million
2016
Haimen animal center began operations and obtained AAALAC credentials；
Established antibody discovery platform；
Established Eucure to engage in clinical and preclinical development of drug candidates。
2018
Biocytogen Boston Corp began operation；
Series B+ funding: RMB 21.65 million,
Series C funding: RMB 260 million.
2019
Developed technology for megabase-scale chromosomal editing and released
RenMab Mice, a fully human antibody mouse model
Obtained approval for commencing Phase I clinical trials of YH001 in patients
with advanced solid tumors in the U.S.
Completed the series D round financing and raised an aggregate amount of
approximately RMB500 million
2020
Completed first patient screening for Phase I clinical studies of YH001, YH002
and YH003 in Australia
Launched Project Integrum, a large-scale in vivo antibody discovery
program
Completed the series D+ round financing and raised an aggregate amount of
approximately RMB850 million
2021
Completed first patient screening for Phase I clinical study of YH001 and
obtained approval to initiate Phase I clinical trial of YH003 in the PRC
Completed Phase I clinical trial of YH003, entered Phase II clinical study of
YH003 in Australia, and obtained approvals to commence Phase II clinical trials
for YH001 and YH003 in the U.S. and Phase I clinical trial of YH004 in
Australia.
Completed the cross-over round financing and raised an aggregate amount of
approximately RMB311.0 million
On September
Listed on the Main Board of the Stock Exchange of Hong Kong
On March
Established Biocytogen Europe Innovation Center in Heidelberg
+86-010-56967680
Copyright © 2022 Biocytogen. All Rights Reserved
Powered by Fractal-technology